Clinical implications of molecular alterations in intraductal carcinoma of the prostate


Benjamin Miron, Shuanzeng Wei, Yasmine Baca, Daniel Herchenhorn, Isabela Cunha, Kevin Zarrabi, Jacqueline Brown, Matthew Oberley, Chadi Nabhan, Emmanuel Antonarakis, Daniel Geynisman, Rana McKay


  • This data suggests that IDC-P harbors targetable molecular alterations in DDR genes (BRCA1/2 and CDK12) with approved targeted agents (e.g. PARP inhibitors).
  • We also found enrichment of oncogenic FOXA1 mutations in IDC-P which are associated with prostate cancer progression, castrate-resistance and an unfavorable prognosis.
  • There were no tumors which demonstrated mismatch-repair deficiency (dMMR) or microsatellite instability and none of the profiled tumors had a high tumor mutational burden ( > = 10 mutations/megabase).
  • Further efforts are ongoing to expand this cohort of IDC-P cases and compare them with a matched cohort of pure adenocarcinoma cases and will include analysis of key RNA expression signatures.
Download Publication